Purpose of the development: For the treatment of dermatophytes, yeast and polymorphic fungi, mycoses with secondary infection (foot mycoses, nails, seborrheic dermatitis, sebopsoriasis, mixed fungal infections), and also effective against staphylococci and streptococci.

Recommended application field: Medicine, pharmacology, veterinary science, beekeeping, textile industry.

Advantages over analogues: Wide range of action; low toxicity (LD50 5.4 g / kg in rats,> 5.0 g / kg in mice).

The development stage readiness: Ready for application

Description of the development:
()
The release of the drug in Ukraine will make it possible: to refuse from import substitution, to significantly reduce the price of the drug, and also to conduct further searches for the use of BIFAZOL in various fields (medicine, veterinary medicine, beekeeping, textile industry, etc.), export the drug to the CIS countries and the far foreign countries.

Information about newness of the development:
there are Ukrainian patents -- 2 items

corresponds technical description
Guarantees stable results getting

Possibility of transfer abroad:
Combinated reduction to industrial level
Creation of joint enterprise

Photo

Country Ukraine

For additional information turn to:
E-mail: gal@uintei.kiev.ua